Kazuaki Enya

Efficacy and safety of fasiglifam ( <scp>TAK</scp> ‐875), a <scp>G</scp> protein‐coupled receptor 40 agonist, in <scp>J</scp> apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase <scp>III</scp> trial

Kohei Kaku, Kazuaki Enya, Ryou Nakaya et al. · Diabetes Obesity and Metabolism · 2015 · 132 citations · Full text

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

Hiromi Rakugi, Kazuaki Enya, Kenkichi Sugiura et al. · Hypertension Research · 2012 · 115 citations · Full text

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas

Yutaka Osuga, Kazuaki Enya, Kentarou Kudou et al. · Obstetrics and Gynecology · 2019 · 90 citations · Full text

Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women

Yutaka Osuga, Kazuaki Enya, Kentarou Kudou et al. · Fertility and Sterility · 2019 · 69 citations · Full text

Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III study

Kouhei Kaku, Kazuaki Enya, Ryou Nakaya et al. · Diabetes Obesity and Metabolism · 2016 · 62 citations

Metabolic Syndrome, Diabetes Management, Agonist Fasiglifam +14